Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10723720 | 1.00 | ALDH1A1 (0.37) | ALDH1A1EPHX1MAPTMEN1KMT2A | |
| SCHEMBL134210 | 1.00 | ALDH1A1 (0.37) | ALDH1A1EPHX1MAPTMEN1KMT2A | |
| SCHEMBL20657055 | 0.90 | EPHX1 (0.35) | ALDH1A1EPHX1MAPTTRPA1TRPM8 | |
| SCHEMBL19243832 | 0.86 | — | — | |
| SCHEMBL1506461 | 0.85 | CHRNB2 (0.36) | MAPTCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL890380 | 0.85 | CHRNB2 (0.36) | MAPTCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1060400 | 0.85 | CHRNB2 (0.36) | MAPTCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4279 | 0.85 | — | — | |
| SCHEMBL19996349 | 0.84 | CES2 (0.42) | ALDH1A1EPHX1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15764742 | 0.82 | CES2 (0.46) | ALDH1A1EPHX1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010115869-A1 | PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-10-14 | — | — | WO | claimed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3490974-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| CN-109906218-B | Spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| WO-1999041255-A1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5661153-A | FOR TREATING ALLERGIES, ASTHMA, DERMATITIS, GRAFT REJECTIONS | JAPAN ENERGY CORPORATION (JP) | 1997-08-26 | — | — | US | disclosed |
| US-5605920-A | HERBICIDES, SELECTIVE IN PADDY FIELDS | NIHON BAYER AGROCHEM K.K. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | disclosed |
| CN-1138574-A | Novel tetrazolinones | BAYER AGROCHEM KK (JP) | 1996-12-25 | — | — | CN | disclosed |
| EP-0733625-A1 | 1-Substituted-tetrazolinones and their use as herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0700908-A1 | 1-Arylpyrimidine derivatives and pharmaceutical use thereof | JAPAN ENERGY CORPORATION (JP) | 1996-03-13 | — | — | EP | disclosed |
| EP-0195497-B1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1989-07-12 | — | — | EP | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885EPHX1 949/4885MAPT 2576/4885 |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | ALDH1A1 2489/4885EPHX1 2987/4885MAPT 1898/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ALDH1A1 2489/4885EPHX1 2987/4885MAPT 1898/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885EPHX1 949/4885MAPT 2576/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885EPHX1 949/4885MAPT 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.